TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7540789

Group type: EXPERIMENTAL
Intervention: 4% hydroxyethyl starch 120/0.7
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3% dextran 70
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 120/0.7
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 2025524

Group type: EXPERIMENTAL
Intervention: Triple therapy (cyclosporine, prednisone, azathioprine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment (prednisone, azathioprine)
Number of subjects: 0
Study: 6113483

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin (0.075 IU/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular insulin (0.075 IU/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous insulin (0.075 IU/kg)
Number of subjects: 0
Study: 30621794

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive control training program (30 min daily, 5 days/week for 12 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive control training program
Number of subjects: 70
Study: 28914250

Group type: COMPARATOR
Intervention: Pit and fissure sealant placed without bonding agent (GROUP A)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pit and fissure sealant placed following sixth generation bonding agent (ADPER PROMT) (GROUP B)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pit and fissure sealant placed following seventh generation bonding agent (OPTIBOND) (GROUP C)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pit and fissure sealant placed following eighth generation bonding agent (FUTURA BOND DUAL CURE) (GROUP D)
Number of subjects: 37
Study: 25886805

Group type: EXPERIMENTAL
Intervention: Yoga intervention (16 classes over 8 weeks)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 57
Study: 24427795

Group type: EXPERIMENTAL
Intervention: Crystalens HD single‐optic accommodating IOL
Number of subjects: 64

Group type: COMPARATOR
Intervention: Tecnis ZCB00 aspheric monofocal IOL
Number of subjects: 64
Study: 21338971

Group type: EXPERIMENTAL
Intervention: Intracavitary pyloromyotomy (ICP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Extracavitary pyloromyotomy (ECP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both ICP and ECP
Number of subjects: 40
Study: 19723739

Group type: EXPERIMENTAL
Intervention: START program (short-term acute residential treatment)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Hospital psychiatric unit
Number of subjects: 93
Study: 17428343

Group type: EXPERIMENTAL
Intervention: Nutrilon Omneo (new formula; NF)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 38
Study: 15065964

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg, administered daily or targeted to high‐risk drinking situations
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Targeted administration of Naltrexone
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Naltrexone (targeted administration)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 11557107

Group type: EXPERIMENTAL
Intervention: Cisplatin 120 mg/m(2), mitomycin C 8 mg/m(2), vindesine 3 mg/m(2) per cycle
Number of subjects: 221

Group type: COMPARATOR
Intervention: Carboplatin 500 mg/m(2), mitomycin C 8 mg/m(2), vindesine 3 mg/m(2) per cycle
Number of subjects: 221

Group type: COMPARATOR
Intervention: Carboplatin arm
Number of subjects: 221
Study: 9662230

Group type: EXPERIMENTAL
Intervention: Supine Bicycle Stress Echocardiography (SBSE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treadmill Testing
Number of subjects: 20
Study: 7730842

Group type: EXPERIMENTAL
Intervention: General Well-Being Adjustment Scale (GWB)
Number of subjects: 545
Study: 3190969

Group type: EXPERIMENTAL
Intervention: Plain solution (0.5% bupivacaine 3 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hyperbaric solution (0.5% bupivacaine 3 ml)
Number of subjects: 20
Study: 31655020

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 5482

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5482
Study: 29231315

Group type: EXPERIMENTAL
Intervention: Acupuncture with regulating mind and spleen (6 weeks, applied at specific acupuncture points, 3 times a week).
Number of subjects: 81

Group type: COMPARATOR
Intervention: Pinaverium bromide tablet (50 mg, 3 times a day for 6 weeks).
Number of subjects: 81
Study: 25252296

Group type: EXPERIMENTAL
Intervention: 10 mg oral nicorandil
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 20 mg oral nicorandil
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (no nicorandil)
Number of subjects: 138
Study: 24315282

Group type: EXPERIMENTAL
Intervention: 25% sucrose
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Nonnutritional sucking
Number of subjects: 84
Study: 21184171

Group type: EXPERIMENTAL
Intervention: Neighborhood disorder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fear of victimization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in neighborhood disorder
Number of subjects: 0
Study: 18337343

Group type: EXPERIMENTAL
Intervention: AS + AQ (3 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AS + SP (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AS monotherapy (5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AS + SP
Number of subjects: 0

Group type: COMPARATOR
Intervention: AS + AQ
Number of subjects: 0
Study: 17181919

Group type: EXPERIMENTAL
Intervention: Collagen-PVP (2 ml, 3.4 mg of collagen)
Number of subjects: 30
Study: 14677007

Group type: EXPERIMENTAL
Intervention: Monofilament tape
Number of subjects: 100

Group type: COMPARATOR
Intervention: Multifilament tape
Number of subjects: 100
Study: 10632418

Group type: COMPARATOR
Intervention: CC (100 mg daily for 5 days)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: CC (100 mg daily for 5 days) plus ethinyl E2 (0.05 mg daily for 5 days)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 64
Study: 9187782

Group type: EXPERIMENTAL
Intervention: 10 ml.kg‐1 Ringer's Lactate solution over 20 min (preload group, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No crystalloid infusion (no‐preload group, n = 10)
Number of subjects: 20
Study: 7903180

Group type: EXPERIMENTAL
Intervention: Multisensory stimulation
Number of subjects: 0
Study: 3922395

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 16

Group type: COMPARATOR
Intervention: Chlorpheniramine
Number of subjects: 16
Study: 31687186

Group type: EXPERIMENTAL
Intervention: Slim piezoelectric tips
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual mini-five area-specific curets
Number of subjects: 20
Study: 29098432

Group type: EXPERIMENTAL
Intervention: Endoloop
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Stapler
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hem-o-lok
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: DS clips
Number of subjects: 120
Study: 26595751

Group type: EXPERIMENTAL
Intervention: 27 gauge needle
Number of subjects: 36

Group type: COMPARATOR
Intervention: 23 gauge needle
Number of subjects: 36

Group type: COMPARATOR
Intervention: 21 gauge needle
Number of subjects: 36
Study: 24611636

Group type: EXPERIMENTAL
Intervention: Whole grain foods rich in lignans (30 g/d of breakfast cereals or biscuits, 80 g/d of whole grain pasta)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Refined grain foods
Number of subjects: 13
Study: 22235107

Group type: COMPARATOR
Intervention: Control group (standard fasting)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo group (water)
Number of subjects: 48

Group type: COMPARATOR
Intervention: CHO group (water with 50 g maltodextrine)
Number of subjects: 48

Group type: COMPARATOR
Intervention: GLN group (water with 50 g maltodextrine plus 40 g GLN)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: GLN group
Number of subjects: 48

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 19996769

Group type: EXPERIMENTAL
Intervention: Isometric knee extension training for 3 months
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Detraining period
Number of subjects: 8
Study: 17708711

Group type: EXPERIMENTAL
Intervention: Denosumab 6, 14, or 30 mg every 3 months
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Denosumab 14, 60, 100, or 210 mg every 6 months
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly
Number of subjects: 412
Study: 16094663

Group type: EXPERIMENTAL
Intervention: Venlafaxine (75-225 mg/day)
Number of subjects: 16
Study: 11965558

Group type: EXPERIMENTAL
Intervention: Color ultrasound imaging of the urethra
Number of subjects: 28
Study: 9535245

Group type: EXPERIMENTAL
Intervention: DTPtxd
Number of subjects: 3450

Group type: COMPARATOR
Intervention: DT
Number of subjects: 3450
Study: 7657849

Group type: EXPERIMENTAL
Intervention: Nicoderm
Number of subjects: 24

Group type: COMPARATOR
Intervention: Habitrol
Number of subjects: 24
Study: 2510652

Group type: EXPERIMENTAL
Intervention: Diltiazem (D+) group: 14 patients, receiving a loading dose of 0.3 mg/kg followed by a continuous IV infusion of 2 micrograms/kg/d, then orally (120-180 mg/d) throughout the study.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (D-) group: 16 patients, no diltiazem treatment.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diltiazem (D+) group: 14 patients.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (D-) group: 16 patients.
Number of subjects: 30
Study: 29916944

Group type: EXPERIMENTAL
Intervention: Anxiety symptoms (measured by validated self‐administered questionnaires)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Trait anxiety (measured by Spielberger Trait Anxiety)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Cognitive anxiety (measured by HADS Anxiety Subscale)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Depressive symptoms (measured by HADS Depression Subscale and Beck Depression Inventory)
Number of subjects: 121
Study: 27581434

Group type: EXPERIMENTAL
Intervention: Flexyn2a (10 μg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flexyn2a with aluminum adjuvant
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25428164

Group type: EXPERIMENTAL
Intervention: Sampling kit received by mail
Number of subjects: 3596

Group type: EXPERIMENTAL
Intervention: Conventional container received by mail
Number of subjects: 3596

Group type: EXPERIMENTAL
Intervention: Sampling kit received at the clinic
Number of subjects: 3596

Group type: COMPARATOR
Intervention: Conventional container received at the clinic
Number of subjects: 3596

Group type: EXPERIMENTAL
Intervention: Both sampling kit and conventional container
Number of subjects: 3596
Study: 21815994

Group type: EXPERIMENTAL
Intervention: Osteotome technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional drilling technique
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 30
Study: 20851942

Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control
Number of subjects: 131
Study: 18465341

Group type: EXPERIMENTAL
Intervention: CEF (cyclophosphamide, epirubicin, and fluorouracil)
Number of subjects: 980

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: TOP2A aberrations (amplifications and deletions)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: TOP2A deletions
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: TOP2A amplifications
Number of subjects: 980
Study: 17169794

Group type: EXPERIMENTAL
Intervention: Very high-dose methotrexate (33.6 g/m2)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Very high-dose methotrexate (33.6 g/m2) with intensified systemic and intrathecal therapy
Number of subjects: 484

Group type: COMPARATOR
Intervention: Cranial radiation plus intrathecal methotrexate
Number of subjects: 484

Group type: COMPARATOR
Intervention: Intrathecal methotrexate alone
Number of subjects: 484
Study: 12668651

Group type: EXPERIMENTAL
Intervention: Sequential doxorubicin (A) x 4 -> paclitaxel (T) x 4 -> cyclophosphamide (C) x 4 every 2 weeks with filgrastim
Number of subjects: 2005

Group type: EXPERIMENTAL
Intervention: Concurrent doxorubicin and cyclophosphamide (AC) x 4 -> paclitaxel (T) x 4 every 2 weeks with filgrastim
Number of subjects: 2005

Group type: COMPARATOR
Intervention: Sequential doxorubicin (A) x 4 -> paclitaxel (T) x 4 -> cyclophosphamide (C) x 4 every 3 weeks
Number of subjects: 2005

Group type: COMPARATOR
Intervention: Concurrent doxorubicin and cyclophosphamide (AC) x 4 -> paclitaxel (T) x 4 every 3 weeks
Number of subjects: 2005
Study: 10877376

Group type: EXPERIMENTAL
Intervention: Threshold‐related suprathreshold examination strategy
Number of subjects: 322

Group type: COMPARATOR
Intervention: FASTPAC threshold central visual field examination strategy
Number of subjects: 322
Study: 9088999

Group type: EXPERIMENTAL
Intervention: Doxophylline 400 mg orally, 3 times daily
Number of subjects: 67
Study: 8251249

Group type: EXPERIMENTAL
Intervention: Pre-brush rinse containing 0.03% triclosan and 0.125% copolymer, rinsed twice daily for 6 months.
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo pre-brush rinse, rinsed twice daily for 6 months.
Number of subjects: 125
Study: 3700197

Group type: EXPERIMENTAL
Intervention: HbA1 results made available to group A
Number of subjects: 146

Group type: COMPARATOR
Intervention: HbA1 results withheld from group B
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Knowledge of HbA1 concentrations by physician and patient/parent
Number of subjects: 146

Group type: COMPARATOR
Intervention: Patients with initial HbA1 less than 12.7%
Number of subjects: 146
Study: 29858688

Group type: EXPERIMENTAL
Intervention: 15 g Arg/day
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 30 g Arg/day
Number of subjects: 101

Group type: COMPARATOR
Intervention: 0 g Arg/day (placebo)
Number of subjects: 101
Study: 29953191

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 80 mg
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 81 mg
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 100 mg
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 325 mg
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control group (no IHD)
Number of subjects: 370
Study: 24261900

Group type: EXPERIMENTAL
Intervention: Penile traction therapy (PTT) for 6 months
Number of subjects: 55

Group type: COMPARATOR
Intervention: No intervention (NIG)
Number of subjects: 55
Study: 22909281

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone 0.3 mg/kg stat
Number of subjects: 232

Group type: COMPARATOR
Intervention: Prednisolone 1 mg/kg/day for three days
Number of subjects: 232
Study: 20056845

Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (14% O(2))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hypocapnic hypoxia (14% O(2))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normoxia (21% O(2))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Isocapnic hyperoxia (40% O(2))
Number of subjects: 9
Study: 18230747

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment for OSAHS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of co-existent SDB
Number of subjects: 0
Study: 16686082

Group type: EXPERIMENTAL
Intervention: Antiretroviral Medication Complexity Index (AMCI)
Number of subjects: 0
Study: 14974733

Group type: EXPERIMENTAL
Intervention: Difructose anhydride III (DFAIII) - 10 g in a 200 mL water solution
Number of subjects: 9

Group type: COMPARATOR
Intervention: Lactulose - control group
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sucrose - control group
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Difructose anhydride III (DFAIII)
Number of subjects: 9
Study: 10990166

Group type: EXPERIMENTAL
Intervention: rgp160 vaccine
Number of subjects: 142

Group type: COMPARATOR
Intervention: IFN-gamma
Number of subjects: 142
Study: 9175352

Group type: EXPERIMENTAL
Intervention: Perforated (P-type) RBBs
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Etched (E-type) RBBs
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Rebonded RBBs
Number of subjects: 157
Study: 1437429

Group type: EXPERIMENTAL
Intervention: High catheters placed in the thoracic aorta (closest to the sixth to eighth thoracic vertebra)
Number of subjects: 970

Group type: COMPARATOR
Intervention: Low catheters placed in the abdominal aorta (closest to the third to fifth lumbar vertebra)
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Neonates weighing 750 to 999 g
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Neonates weighing 1000 to 1499 g
Number of subjects: 970
Study: 3957541

Group type: EXPERIMENTAL
Intervention: Breast cancer screening
Number of subjects: 0
Study: 31824507

Group type: EXPERIMENTAL
Intervention: CMV glycoprotein B (gB) vaccine
Number of subjects: 40
Study: 28795416

Group type: EXPERIMENTAL
Intervention: GPA 100 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Creatine 5 g
Number of subjects: 24
Study: 25772962

Group type: EXPERIMENTAL
Intervention: Nasal packs removed after 12 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nasal packs removed after 24 hours
Number of subjects: 60
Study: 22045782

Group type: EXPERIMENTAL
Intervention: Dance-based therapy (18 sessions of low-impact therapy)
Number of subjects: 27
Study: 21633074

Group type: EXPERIMENTAL
Intervention: HCF diet
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: HP diet
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Mix diet
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 111
Study: 19920714

Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg twice daily)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 16790988

Group type: EXPERIMENTAL
Intervention: Unilateral electrical stimulation (ES) of the globus pallidus internus
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Unilateral lesion of the globus pallidus internus
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both interventions (lesions and ES)
Number of subjects: 18
Study: 15150305

Group type: EXPERIMENTAL
Intervention: Direct-mail FOBT with reminders
Number of subjects: 1451

Group type: EXPERIMENTAL
Intervention: Direct-mail FOBT without reminders
Number of subjects: 1451

Group type: COMPARATOR
Intervention: Control group (questionnaire only)
Number of subjects: 1451
Study: 11717600

Group type: EXPERIMENTAL
Intervention: Planned strategy intervention group (n = 80)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Usual-care control group (n = 189)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Planned strategy intervention group (phase 2, n = 366)
Number of subjects: 366
Study: 9433585

Group type: EXPERIMENTAL
Intervention: Quantitative disease classification (Q1)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Dichotomous disease classification (AF)
Number of subjects: 367
Study: 8328559

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 3080286

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms, 5 doses over 24 hours)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (5 doses over 24 hours)
Number of subjects: 30
Study: 30040753

Group type: EXPERIMENTAL
Intervention: Cathodal tsDCS
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Anodal tsDCS
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham tsDCS
Number of subjects: 6
Study: 27875942

Group type: EXPERIMENTAL
Intervention: pico-Tesla Transcranial Magnetic Stimulation (pT-TMS) applied with magnetic field amplitude of 1-7.5 pT and frequency of 8-13 Hz
Number of subjects: 10
Study: 25319870

Group type: EXPERIMENTAL
Intervention: High-dose vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dose vaccine
Number of subjects: 0
Study: 21744005

Group type: EXPERIMENTAL
Intervention: Amino acid supplementation (AA, 51 g of amino acids and 40 g of carbohydrate)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo supplementation (PL, 91 g of carbohydrate)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Trail walking in the mountains
Number of subjects: 21
Study: 20188470

Group type: EXPERIMENTAL
Intervention: Pain+Distraction (video games requiring high attention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pain Alone (capsaicin+heat without distraction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distraction Alone (video games without pain stimulus)
Number of subjects: 0
Study: 17991698

Group type: EXPERIMENTAL
Intervention: Diazepam (single oral dose)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Baclofen (single oral dose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 8
Study: 15647752

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systematic reviews
Number of subjects: 0
Study: 11812698

Group type: EXPERIMENTAL
Intervention: Paravertebral blockade (PVB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 30
Study: 10366113

Group type: EXPERIMENTAL
Intervention: Bovine type II collagen (CII), 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 7564450

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2289979

Group type: EXPERIMENTAL
Intervention: Colloids, red cells, dobutamine, and vasodilators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased DO2 and VO2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 7294546

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 6